Aiguo G. Xu

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Acinetobacter baumannii inhibits the PLK2/FoxO axis to induce oxidative stress and cell barrier dysfunction.

Acinetobacter baumannii inhibits the PLK2/FoxO axis to induce oxidative stress and cell barrier dysfunction.

Journal: Microbiology spectrum

Published: August 21, 2026

International Consensus on Severe Lung Cancer-The Second Edition.

International Consensus on Severe Lung Cancer-The Second Edition.

Journal: Translational lung cancer research

Published: March 21, 2026

SIRT1 activation restores PINK1-dependent mitophagy to reverse airway barrier dysfunction in Acinetobacter baumannii infection.

SIRT1 activation restores PINK1-dependent mitophagy to reverse airway barrier dysfunction in Acinetobacter baumannii infection.

Journal: Free radical biology & medicine

Published: December 09, 2025

Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.

Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: October 02, 2025

Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis.

Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis.

Journal: Asian journal of pharmaceutical sciences

Published: June 03, 2025

Correction: Zafirlukast ameliorates lipopolysaccharide and bleomycin-induced lung inflammation in mice.

Correction: Zafirlukast ameliorates lipopolysaccharide and bleomycin-induced lung inflammation in mice.

Journal: BMC pulmonary medicine

Published: April 11, 2025

Bergenin and vitexin delivery platform using mouse lung fibroblasts-derived exosomes for bleomycin-induced pulmonary fibrosis therapy.

Bergenin and vitexin delivery platform using mouse lung fibroblasts-derived exosomes for bleomycin-induced pulmonary fibrosis therapy.

Journal: International journal of pharmaceutics

Published: January 15, 2025

Widespread Molecular Imprints in the Serum Proteome of COVID-19 Convalescents Uncovering Immune System Sequelae.

Widespread Molecular Imprints in the Serum Proteome of COVID-19 Convalescents Uncovering Immune System Sequelae.

Journal: Molecular & cellular proteomics : MCP

Published: January 04, 2025

Treatment of Bleomycin-induced Pulmonary Fibrosis by Intratracheal Instillation Administration of Ellagic Acid-Loaded Chitosan Nanoparticles.

Treatment of Bleomycin-induced Pulmonary Fibrosis by Intratracheal Instillation Administration of Ellagic Acid-Loaded Chitosan Nanoparticles.

Journal: AAPS PharmSciTech

Published: November 27, 2024

Formononetin-Loaded PLGA Large Porous Microparticles via Intratracheal Instillation for Bleomycin-Induced Pulmonary Fibrosis Treatment.

Formononetin-Loaded PLGA Large Porous Microparticles via Intratracheal Instillation for Bleomycin-Induced Pulmonary Fibrosis Treatment.

Journal: AAPS PharmSciTech

Published: November 10, 2024

Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis.

Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis.

Journal: European journal of clinical pharmacology

Published: August 02, 2024

Causal relationship between gut microbiota and gynecological tumor: a two-sample Mendelian randomization study.

Causal relationship between gut microbiota and gynecological tumor: a two-sample Mendelian randomization study.

Journal: Frontiers in microbiology

Published: April 26, 2024

Showing 1-12 of 37

Last Updated: 09/26/2026